Novalar Pharmaceuticals has announced that results from the first OraVerse dental practice survey will be presented by Richard Ghalie, MD, chief medical officer for Novalar March 3-6, 2010, at the annual meeting of the American Association of Dental Research in Washington, D.C.
The survey was conducted with 49 dentists and 370 patients. Participating dentists were provided with 10 cartridges of OraVerse and a survey to provide to their patients to record their experience with the product.
Of those patients who participated in the survey:
* 86% reported that OraVerse improved their dental experience
* 82% would recommend OraVerse to their friends and family
* 80% would request OraVerse again
Doctors also reported positive results:
* 93% reported that OraVerse addresses an existing need
* 91% reported OraVerse met their expectations
Dr. Ghalie said the experience of patients in the survey were consistent with results from Novalar's published controlled studies. OraVerse injections were well tolerated with an incidence of reactions comparable to that of local anesthetics. In addition, the results show high patient satisfaction with the product, favorable assessment by the dentists and the overall view that OraVerse fills an existing need in dentistry.
"We were very pleased with the results of this survey," stated Donna Janson, president and chief executive officer of Novalar.
"This validates what has been known for many years—patients do not like the loss of sensation and function caused by local anesthetics, dental professionals recognize the need for a reversal agent such as OraVerse and both patients and dentists see the value in this solution."
For more information, go to Novalar.
To read more about Novalar, go to Novalar.
To comment on this topic, go to PennWell Dental Community site.
